BioWorld

July 13, 2006

ARYx Signs P&G To $435M Agreement For Lead GI Drug

Privately held ARYx Therapeutics Inc. signed its first major partnership since its founding in 1998, granting to Procter & Gamble Pharmaceuticals Inc. worldwide development and commercialization rights to ATI-7505 in gastrointestinal disorders. (BioWorld Today) Read More

Genentech's Solid Earnings Dampened By Avastin Sales

FDA Approves Single-Tablet HIV Drug From Gilead, BMS

Genzyme Earnings Bounce Back; Second Quarter Solid

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...